Table 4

Answers to multiple choice questions of survey section 2

QuestionsMultiple-choice responsesAll, n (%)H CPR, n (%)M CPR, n (%)L CPR, n (%)
N=75N=17N=51N=7
1. Do you have any preference in the schedule of ICI choice for the treatment of CPs?☐ Yes, I prefer the schedule with the shorter interval31 (41.3)9 (52.9)21 (41.2)1 (14.3)
☐ Yes, I prefer the schedule with the longer interval39 (52)7 (41.2)26 (51)6 (85.7)
☐ No, the schedule interval is not a criteria for ICI choice in my clinical practice5 (6.7)1 (5.9)4 (7.8)0 (0)
2. Do you have currently (during COVID-19 pandemic) any preference in the schedule of ICIs for the treatment of CPs?☐ Yes, I prefer the schedule with the shorter interval0 (0)0 (0)0 (0)0 (0)
☐ Yes, I prefer the schedule with the longer interval58 (77.3)13 (76.5)38 (74.5)7 (100)
☐ No, the schedule interval is not a criteria for ICI choice in my current clinical practice17 (22.7)2 (23.5)13 (25.5)0 (0)
3. Have you modified the dose of steroids you give in case of ICI adverse events?☐ Yes, I have reduced the dose3 (4)1 (1.9)1 (2)1 (14.3)
☐ No, I continue to follow the recommendation for the AE management72 (96)16 (94.1)50 (98)6 (85.7)
4. Has the COVID-19 pandemic changed your treatment choice for CP-ICI in case of alternative treatments like chemotherapy, where applicable, as for clinical practice guidelines?☐ Yes6 (8)1 (5.9)5 (9.8)0 (0)
☐ No69 (92)16 (94.1)46 (90.2)7 (100)
5. Has the COVID-19 pandemic changed your treatment choice for CP-ICI in case of alternative treatments like targeted therapy, where applicable, as for clinical practice guidelines?☐ Yes9 (12)2 (11.8)6 (11.8)1 (14.3)
☐ No66 (88)15 (88.2)45 (88.2)6 (85.7)
6. Are the CP-ICI preferentially seen in COVID-19 clear institutions?☐ Yes29 (38.7)6 (35.3)21 (41.2)2 (28.6)
☐ No46 (61.3)11 (64.7)30 (58.8)5 (71.4)
7. Do you use G-CSF in case of CP-ICIs with no febrile neutropenia (when used ±chemotherapy)?☐ Yes12 (16)1 (5.9)11 (21.6)0 (0)
☐ No63 (84)16 (94.1)40 (78.4)7 (100)
8. Has this decision been changed by the COVID-19 pandemic?☐ Yes6 (8)2 (11.8)4 (7.8)0 (0)
☐ No69 (92)15 (88.2)47 (92.2)7 (100)
9. Have the CP-ICI been managed in expert centers for immunotherapy?☐ Yes53 (70.7)15 (88.2)34 (66.7)4 (57.1)
☐ No22 (29.3)2 (11.8)17 (33.3)3 (42.9)
10. Has this decision been changed by the COVID-19 pandemic?☐ Yes1 (1.3)0 (0)1 (2)0 (0)
☐ No74 (98.7)17 (100)50 (98)7 (100)
11. Do you prefer to delay ICI start in lung cancer patients because of potential lung toxicity considering the high lung tropism of SARS-CoV-2 virus and its risk of ARDS?☐ Yes8 (10.7)3 (17.6)4 (7.8)1 (10.7)
☐ No67 (89.3)14 (82.4)47 (92.2)6 (85.7)
12. In your institution, has surgery for CP been delayed because of the COVID-19 pandemic?☐ Yes35 (46.7)9 (52.9)24 (47.1)2 (28.6)
☐ No40 (53.3)8 (47.1)27 (52.9)5 (71.4)
  • H CPR: high (H) prevalence regions with more than 10,000 positive patients, M CPR: medium (M) prevalence regions with positive patients less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 4000 positive patients.

  • ARDS, acute respiratory distress syndrome; CP, cancer patient; CP-ICI, cancer patients undergoing or candidate for immune checkpoint inhibitor; ICI, immune checkpoint inhibitor; N, number.